Xiangmin Decheng Capital Ch... Net Worth

Insiders trading at Alpine Immune Sciences Inc

Over the last 7 years, insiders at Alpine Immune Sciences Inc have traded over $91,012,519 worth of Alpine Immune Sciences Inc stock and bought 8,061,426 units worth $69,477,679 . The most active insiders traders include Peter A. Thompson, Advisors Llc Orbi Med Capit... a James N Topper. On average, Alpine Immune Sciences Inc executives and independent directors trade stock every 37 days with the average trade being worth of $18,201,670. The most recent stock trade was executed by Stanford L Peng on 8 May 2024, trading 271,792 units of ALPN stock currently worth $668,608.

What does Alpine Immune Sciences Inc do?

founded in 2015 by a team responsible for the fda's approval of the world's first cancer immunotherapy and experts in the field of recombinant protein based immunotherapies, alpine immune sciences was created to capitalize on our unique understanding of immunology, modifying the complexities of the immune synapse for the benefit of patients living with cancer, autoimmune disorders, and other diseases. traded on nasdaq under ticker alpn.

Alpine Immune Sciences Inc executives and stock owners

Alpine Immune Sciences Inc executives and other stock owners filed with the SEC include:

• Mitchell Gold,
  Executive Chairman of the Board, Chief Executive Officer
• Stanford Peng,
  President and Head of Research and Development
• Paul Rickey,
  Chief Financial Officer, Senior Vice President, Corporate Secretary
• Dr. Mitchell H. Gold M.D.,
  Exec. Chairman & CEO
• Dr. Stanford Peng M.D., Ph.D.,
  Pres and Head of R&D
• Paul Rickey,
  Sr. VP, CFO, Treasurer & Sec.
• Natasha Hernday,
  Director
• Laurence Watts,
  IR Contact Officer
• James Topper,
  Independent Director
• Peter Thompson,
  Independent Director
• Christopher Peetz,
  Independent Director
• Xiangmin Cui,
  Independent Director
• Robert Conway,
  Independent Director
• Jay Venkatesan,
  Director
• Wayne Gombotz,
  Chief Technology Officer
• Alexander Sharif,
  Director of Investor Relations & Corp. Devel.
• Dr. Zelanna Goldberg M.D.,
  Chief Medical Officer
• Dr. Pamela Holland Ph.D.,
  Sr. VP of Research
• Dr. Remy Durand Ph.D.,
  Chief Bus. Officer
• Dr. Jan L. Hillson Ph.D., M.D.,
  Sr. VP of Clinical Devel.
• Dr. Wayne R. Gombotz,
  Chief Technology Officer
• Xiangmin Decheng Capital Ch...,
  
• Advisors Llc Orbi Med Capit...,
  
• Paul J Sekhri,
  Director
• Mark James Litton,
  See Remarks
• Andrew Seth Sandler,
  Chief Medical Officer
• Life Sciences Viii, L.P.Fhm...,
  
• Immuno Sciences, L.P.Alpine...,
  
• Advisors Llc Orbi Med Capit...,
  
• Management L.L.C. Tiger,
  10% owner
• Life Sciences Viii, L.P.Fhm...,
  
• Capital China Life Sciences...,
  
• Advisors Llc Orbi Med Capit...,
  
• Zelanna Goldberg,
  Chief Medical Officer
• Life Sciences Viii, L.P.Fhm...,
  
• Capital Global Healthcare F...,
  
• Wolfgang Dummer,
  Chief Medical Officer
• Remy Durand,
  Chief Business Officer
• Ulrich Martin Fuhs,
  Chief Accounting Officer